Please assess the completion status of the following clinical trial:

Trial Title: TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with relapsed (second or subsequent bone marrow relapse or bone marrow relapse after allo-SCT) or refractory (not achieving an initial complete response (CR) after 2 cycles of standard chemotherapy) CD19-positive B-acute lymphoblastic leukaemia~* Morphologically confirmed with leukemic blasts in the bone marrow or a quantifiable MRD load of 1x10-4 (by multiparameter flow cytometry and/or quantitative polymerase chain reaction)~* Eligible and fit for allogeneic hematopoietic stem cells transplantation with suitable donor available~* Estimated life expectancy ≥ 12 weeks~* Lansky (age \< 16 years at the time of assent/consent) or Karnofsky (age ≥ 16 years at the time of assent/consent) performance status ≥ 50 Eastern Cooperative Oncology Group ECOG performance status \< 2~Exclusion Criteria:~* Patients/parents unwilling to undergo a follow-up for 15 years~* Foreseeable poor compliance to the study procedures~* CD19-negative B-cell leukaemia~* Evidence of disease progression after cytoreduction~* Uncontrollable CNS leukaemia or neurological symptoms defined as CNS grade 3 (per National Comprehensive Cancer National guidelines). Patients developing grade 3 CNS disease at any time after enrolment will be excluded.~* Absence of suitable HLA matched or mismatched donor~* Weight \< 6 kgs~* Presence of donor-specific anti-HLA antibodies directed against PBLTT52CAR19~* GvHD requiring systemic therapy~* Systemic steroid therapy prednisolone \>0.5mg/kg/day~* Known hypersensitivity to any of the test materials or related compounds~* Active bacterial, fungal, or viral infection not controlled by a standard of care anti-microbial or anti-viral treatment. Uncontrolled bacteraemia/ fungaemia is defined as the ongoing detection of bacteria/fungus on blood cultures despite antibiotic or anti-fungal therapy.~* Uncontrolled viraemia is defined as rising viral loads on two consecutive occasions despite antiviral therapy.~* Risk of pregnancy or non-compliance with contraception (if applicable). Girls of childbearing potential must have been tested negative in a pregnancy test within 14 days prior to inclusion.~* Lactating female participants unwilling to stop breastfeeding~* Intrathecal methotrexate within 4 weeks or intrathecal chemotherapy (e.g Ara-C) within 2 weeks of lymphodepletion~* Less than 2 half-lives from prior therapy with immune checkpoint pathway modifiers to lymphodepletion~* Prior CAR19 therapy known to be associated with ≥Grade 3 cytokine release syndrome (CRS) or ≥Grade 3 drug-related CNS toxicity

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: OTHER): Follow-up period:~For patients achieving molecular remission by day 28, allo-HSCT will be scheduled as soon as practicable. Routine transplant care for 24 months will incorporate the disease monitoring and recording of adverse events of special interest and document elimination of PBLTT52CAR19 through the transplant conditioning period.~For patients with refractory disease at Day 56, the monitoring of adverse events of special interest, the disease outcome will be monitored monthly up to 24 months or until a palliative therapy approach is adopted.~Assessments will be carried out after the treatment period at the following time points: 1m, 2m, 3m, 6m, and 12m, 24m~* Physical examination, ECOG~* Laboratory tests~* Vital signs (temperature, BP, HR, respiratory rate, weight)~* Persistence of PBLTT52CAR19, VCN by qPCR in blood and bone marrow (if sampled)~* Chimerism and MRD in blood and bone marrow (if sampled)~* Adverse events~* Concomitant treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).